Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Matteo Santoni,
Francesco Massari,
Sergio Bracarda,
Giuseppe Procopio,
Michele Milella,
Ugo De Giorgi,
Umberto Basso,
Gaetano Aurilio,
Lorena Incorvaia,
Angelo Martignetti,
Mimma Rizzo,
Giacomo Cartenì,
Enrique Grande,
Marc R. Matrana,
Simon J. Crabb,
Nuno Vau,
Giulia Sorgentoni,
Alessia Cimadamore,
Rodolfo Montironi,
Nicola Battelli
Affiliations
Matteo Santoni
Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100 Macerata, Italy
Francesco Massari
Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, 40138 Bologna, Italy
Sergio Bracarda
Medical and Translational Oncology Unit, Department of Oncology, AziendaOspedaliera Santa Maria, 05100 Terni, Italy
Giuseppe Procopio
Department of Medical Oncology, Istituto Nazionale dei Tumori IRCCS, 20133 Milan, Italy
Michele Milella
Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust (AOUI Verona), P.le L.A. Scuro 10, 37134 Verona, Italy
Ugo De Giorgi
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
Umberto Basso
Department of Medical Oncology, Istituto Oncologico Veneto IOV IRCCS, 35128 Padova, Italy
Gaetano Aurilio
Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy
Lorena Incorvaia
Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy
Angelo Martignetti
Dipartimento Oncologico USL Sud-Est Toscana-Area Senese, Località Campostaggia s.n.c., 53036 Poggibonsi, Italy
We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan–Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- (113, 5%) or third-line (111, 5%) therapy. The median PFS was significantly higher in patients with BMI ≥ 25 (9.9 vs. 7.6 months, p p = 0.003). As third-line therapy, both median PFS (9.2 months vs. 3.9 months, p = 0.029) and OS (39.4 months vs. 11.5 months, p = 0.039) were longer in patients with BMI ≥ 25. BMI was a significant predictor for both PFS and OS at multivariate analysis. We showed that a BMI ≥ 25 correlates with longer survival in patients receiving cabozantinib. BMI can be easily assessed and should be included in current prognostic criteria for advanced RCC.
